Company / Capital Expenditures
BridgeBio Pharma, Inc. Capital Expenditures History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.1M
FY2025
5-year range
$933.0K / $13.2M
FY2021-FY2025
Trend
+17.6%
vs FY2024
Sector context
#111 of 194
Health Care
What the data says
At $1M, BridgeBio Pharma, Inc.'s capital expenditures ranks #111 of 194 in the Health Care sector. Capital Expenditures has fluctuated over the past 9 years, ranging from $464,000 in FY2017 to $13M in FY2023.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of -32.0%.
Declined from $13M to $1M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -38.9%
- 5-Year CAGR
- -32.0%
- 10-Year CAGR
- -
Sector benchmark
#111 of 194 in Health CareTop 57% of 194This company $1.1M Sector average $117.5M
▼
-99.1% below sector average
Key checks
Key Insights
- 5-year CAGR of -32.0%, indicating a declining trend.
- In FY2025, capital expenditures increased 17.6% year-over-year.
- Ranks #111 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1M | +17.6% |
| FY2024 | $933.0K | -93.0% |
| FY2023 | $13.2M | +174.8% |
| FY2022 | $4.8M | +82.8% |
| FY2021 | $2.6M | -64.9% |
| FY2020 | $7.5M | +185.0% |
| FY2019 | $2.6M | +21.1% |
| FY2018 | $2.2M | +369.4% |
| FY2017 | $464.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026